RenovoRx (Nasdaq: RNXT) Revenue
Biotechnology Research • 
2570 W El Camino Real, Ste. 320, United States • 21-50 Employees
RenovoRx (Nasdaq: RNXT) revenue & valuation
| Annual revenue | $662,000 |
| Revenue per employee | $28,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,200,000 |
| Total funding | $34,300,000 |
Key Contacts at RenovoRx (Nasdaq: RNXT)
Philip Stocton
Sr. Global Director Sales And Market Developemnt
Shaun R. Bagai
Ceo
Company overview
| Headquarters | 2570 W El Camino Real, Ste. 320, Mountain View, California 94040, US |
| Phone number | +16502844433 |
| Website | |
| NAICS | 541714 |
| SIC | 384 |
| Employees | 21-50 |
| Socials |
RenovoRx (Nasdaq: RNXT) Email Formats
RenovoRx (Nasdaq: RNXT) uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@renovorx.com), used 40% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@renovorx.com | 40% |
{first initial} | j@renovorx.com | 30% |
{first name}{last name} | johndoe@renovorx.com | 30% |
About RenovoRx (Nasdaq: RNXT)
RenovoRx, Inc. (Nasdaq: RNXT) is developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. FDA-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic IV therapy. RenovoRx’s novel approach to targeted drug-delivery offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. RenovoRx is evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath which is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. IAG is currently under investigation and has not been approved for commercial sale. RenovoRx is actively commercializing its TAMP technology and RenovoCath as a stand-alone device. In Dec. 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume NCI-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
RenovoRx (Nasdaq: RNXT) has 8 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore RenovoRx (Nasdaq: RNXT)'s funding history, including investment rounds, total capital raised, and key backers.
RenovoRx (Nasdaq: RNXT) Tech Stack
Discover the technologies and tools that power RenovoRx (Nasdaq: RNXT)'s digital infrastructure, from frameworks to analytics platforms.
Security
Advertising
Form builders
Analytics
Maps
Font scripts
SEO
JavaScript libraries
Programming languages
Blogs
Analytics
France
United Kingdom
Canada
Australia
Netherlands
Frequently asked questions
4.8
40,000 users
